Phase 1/2 trial of Evomela for autologous transplant in myeloma: schedule optimization and matched comparison with MEL200.
Qaiser Bashir, Peter F Thall, Jitesh D Kawedia et al.
✦ AI-curated · Sources linked
In 30 seconds
This prospective, randomized phase 1/2 trial evaluated Evomela dose and infusion schedule in 60 patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation. Patients received 200 or 225 mg/m² over either 30–60 minutes or 8–9 hours. No grade ≥4 nonhematologic toxicities or day-100 nonrelapse deaths occurred. At day 90, 45% achieved MRD-negative stringent complete response or complete response. Response and toxicity were similar between infusion schedules; higher melphalan exposure was associated with response, but not progression-free survival. A propensity-matched comparison suggested longer progression-free survival with Evomela than with MEL200.
Key findings
- Day-90 MRD-negative stringent complete response or complete response was 45% overall: 43% with short and 47% with long infusions.
- No grade ≥4 nonhematologic toxicities or day-100 nonrelapse mortality occurred.
- Higher melphalan area under the concentration-time curve was associated with MRD-negative response (posterior probability of benefit 0.99), but not with progression-free survival.
- Propensity-matched comparison favored Evomela over MEL200 for progression-free survival (posterior probability of benefit 0.90).
Why it matters
The findings suggest that infusion duration may be flexible without an evident difference in response or toxicity, while melphalan exposure may help explain response variation. The matched comparison also raises the possibility of a progression-free survival advantage over MEL200, although it is not a randomized comparison. Together, these results inform further evaluation of exposure-guided conditioning in myeloma transplantation.
What to keep in mind
The trial included 60 patients, and the comparison with MEL200 used propensity matching rather than randomization. The abstract does not report the magnitude or uncertainty of the progression-free survival difference.